Telus Peptides

CJC-1295 (No DAC)

Growth hormone axis Research compound (not approved for human use)

Growth hormone releasing hormone analog · also known as Mod GRF 1-29, Modified GRF (1-29)

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

CJC-1295 without DAC (also called Mod GRF 1-29) is a growth-hormone releasing hormone analog. The 'No DAC' version has a short duration, producing a short, pulsatile GH release, which is why it is frequently combined with a secretagogue like Ipamorelin.

Commonly reported dosing (5 mg vial)

Reconstituted with 3 mL → 1.667 mg/mL.

Also sold in 10 mg vials.

PhaseDoseVolumeU-100 units
Starting
Weeks 1-2
100 mcg0.06 mL6
Step
Weeks 3-4
150 mcg0.09 mL9
Standard
Weeks 5-6
200 mcg0.12 mL12
Higher
Weeks 7-12 (250-300 mcg reported)
300 mcg0.18 mL18

Frequency: Once daily, commonly at bedtime (some reports use 1-3x daily), subcutaneous · Half-life: ~30 minutes (No DAC form)

Open in calculator

Commonly reported reconstitution steps

  1. Vials are usually brought to room temperature (about 15-20 minutes) first.
  2. 3 mL of bacteriostatic water is added slowly down the inside wall of the 5 mg vial.
  3. The vial is swirled gently until clear, not shaken.
  4. This gives 1.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

CJC-1295 binds the GHRH receptor on the pituitary, amplifying the natural signal to release growth hormone. Without the DAC modification, the effect is brief and pulse-like.

Researched for

  • Studied for short, pulse-like GH release.
  • Studied in combination with ghrelin-mimetic secretagogues (Ipamorelin).

Notes

  • Mostly studied in combination protocols rather than alone.
  • Typical amounts correspond to small volumes on a U-100 syringe.

Sources

Last reviewed 2026-10-06.

Related

Ipamorelin

Growth hormone secretagogue (ghrelin mimetic)

Ipamorelin is a selective growth-hormone secretagogue that stimulates the pituitary to release growth hormone.

10 mg vial · Once daily, often before bed (some reports use 1-3x daily), subcutaneous

CJC-1295 (No DAC) + Ipamorelin 10 mg Blend

Growth-hormone axis blend

This blend pairs a GHRH analog (CJC-1295 No DAC) with a ghrelin-mimetic secretagogue (Ipamorelin) in one vial.

10 mg vial · Once daily, commonly before bed or on waking (some reports use 2x daily), subcutaneous

CJC-1295 (With DAC)

Long-acting growth hormone releasing hormone analog

CJC-1295 with DAC is a long-acting GHRH analog engineered to bind serum albumin, giving a half-life of days rather than minutes.

5 mg vial · Twice weekly (once weekly also described)

GHRP-2

Ghrelin-receptor agonist (growth hormone releasing peptide)

GHRP-2 is a synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor.

5 mg vial · Once daily (multiple daily doses are also described)

Sermorelin

Growth hormone releasing hormone analog

Sermorelin is the first 29 amino acids of human GHRH, the shortest fragment that keeps its full biological activity.

5 mg vial · Once daily at bedtime

Tesamorelin

Growth hormone releasing hormone analog

Tesamorelin is a stabilized GHRH analog that is FDA-approved (Egrifta) for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

10 mg vial · Once daily, subcutaneous